Alcatel Lucent SA (ADR) (ALU): You’re Being Sold the Same Old Story, I Wouldn’t Buy It

Page 1 of 2

Tuesday, I wrote an article entitled, “Cutting Costs Should Not Be Part of This Company’s Plan!” after a report that Alcatel Lucent SA (ADR) (NYSE:ALU) was backing out of its original plan to divest assets as part of its restructuring strategy. This strategy has created gains of more than 100% since November 2012, yet on Tuesday, the stock fell 1.5% as rumors of this strategy falling apart hit the market. Turns out, these “rumors” were correct, and now Alcatel Lucent SA (ADR) (NYSE:ALU) has backed out of its original plan.

Alcatel Lucent SA (ADR) (NYSE:ALU)

Insanity at its best

My first article showed how “cost-cutting” is a bad idea for Alcatel Lucent SA (ADR) (NYSE:ALU). Why? The company has done nothing but “try” to cut costs for the last five years, laying off more than half its workforce and losing 70% of its stock value. Yet, for some reason, the company believes this plan will work.

On Wednesday, the company announced that it intends to cut costs by $1.25 billion and sell another $1.25 billion worth of assets within two years. Furthermore, the company plans to slash $2.5 billion in debt via selling its stock and additional asset sales.

Incredibly, Alcatel Lucent SA (ADR) (NYSE:ALU)’s stock traded higher by 3.2% on this insane proposition. The original plan was to trim its inefficient segments, those producing losses, and then focus on its growing and profitable segments. This would have been much more beneficial to shareholders.

What is the company telling you?

This is a real simple scenario, as the company is telling us three things.

First, there is severe separation within the company as to its direction. Aside from Ben Verwaayen’s resignation as CEO from Alcatel, just shortly after the announced “plan,” the company’s CFO, restructuring advocate, Paul Tufano is now leaving! He has been very vocal in his support of the original restructuring plan, saying it would cost $625 million this year but that major moves would occur. The company’s board, compiled of those from both the original Alcatel and Lucent, have been disconnected since the merger in 2006, and apparently have removed everyone who still supports a leaner and meaner Alcatel Lucent SA (ADR) (NYSE:ALU).

Second, the $2 billion financing was worthless. Alcatel took $2 billion from Goldman Sachs and put its patents up as collateral. Now, the company is aiming to pay off $2.5 billion in debt (Goldman loan), with stock. Essentially, the company is preparing us for financing, or public offerings, indicating that it has no use for the $2 billion as part of a large restructuring program; and that it will dilute shares to pay off the debt.

Third, all of its “asset sales” are already accounted for and priced into the valuation of the company, as they have no plans to make any substantial moves. Keep in mind, the sale of its submarine optical unit for $1.1 billion has already been reported back in January. It hasn’t yet occurred, but judging by the company’s goal of selling “$1.25 billion worth of assets,” it does appear to be the $1.25 billion submarine segment. Thus, no further changes should be expected from this near bankrupt company, which refuses to make substantial changes.

There is so much upside with the original plan

This new “plan” is bad in every way, with the company’s only “plan” to cut more costs and raise more money. It is the quintessential example of insanity: Doing the same thing over-and-over and expecting a different result.

This is a company that posted quarterly sales of $4 billion last quarter, operates in six segments, and four of those segments saw significant growth of more than 5% year-over-year. In other words, Alcatel has about $2.7 billion worth of quarterly sales that is growing at a combined 8% year-over-year rate, nearly $11 billion in annual revenue. The remaining $8.5 billion in annual revenue weighs on the company and pushes operating margins to just 0.37%.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!